ESF-UB Conference in Biomedicine
Pharmacogenetics and Pharmacogenomics: Practical Applications in Routine Medical Practice
6-11 June 2010
In partnership with With Support from
Institut de Recherche Servier
Final Programme |
| SUNDAY 6 June |
17:00 - 19:00: Registration at ESF Desk
19:00 - 19:30: Welcome Drink
19:30: Dinner
| MONDAY 7 June |
SESSION CHAIR: Philippe Beaune - Université Paris Descartes, FR
09.15 - 09.30: INTRODUCTION
Carsten Carlberg, University of Luxembourg, LU
ESF Presentation
09.30 - 10.00 - INTRODUCING LECTURE:
Philippe Beaune - Université Paris Descartes, FR
Lessons from the past, reality of the present and hopes for the future
SESSION 1: Genome Variability, Technology & Methodology
10.00 - 10.30: Laurent Becquemont - Université Paris-Sud, FR
Different types of clinical studies
10.30 - 11.00: Coffee Break
11.00 - 11.30: Matt Nelson- GlaxoSmithKline, US
Genome wide association studies
SHORT TALKS:
11.30 - 11.45: Chin B. Eap, University of Lausanne, CH
Pharmacological, pharmacogenetics and clinical studies on methadone: a “From the bench to the bedside “ paradigm
11.45 - 12.00: Caroline Samer, Geneva University Hospitals, CH
Reduced oxycodone antinociceptive effects in CYP2D6 poor metabolizers and increased toxicity and pharmacodynamics in CYP2D6 ultrarapid metabolizers and/or after CYP3A drug inhibition
12.00 - 12.15: Andrew Somogyi, University of Adelaide, AU
Towards an international consensus on guidelines for the reporting and interpretation of pharmacogenetic tests in clinical practice
12.30: Lunch
15.30 - 16.00: Coffee Break
SESSION 2: Pharmacogenomics of ADRs
SESSION CHAIR: Mikko Niemi - Department of Clinical Pharmacology, University of Helsinki, FI
16.00 - 16.10: Ann Daly - Pharmacogenetics Group, Institute of Cellular Medicine, Newcastle University Medical School, UK
Initial overview on pharmacogenomics of ADRs
16.10 - 16.35: Ana Alfirevic - University of Liverpool, UK
Pharmacogenetics of drug hypersensitivity
16.35 - 17.10: Ann Daly - Pharmacogenetics Group, Institute of Cellular Medicine, Newcastle University Medical School, UK
Pharmacogenomics of drug induced liver injury (DILI)
17.10 - 17.45: Mikko Niemi - Department of Clinical Pharmacology, University of Helsinky, SF
Pharmacogenetics of Statin-induced myopathy
SHORT TALK:
17.45 - 18.00: Hans Peter Arnold, Illumina Deutschland GmbH, DE
A new multiplexed genotyping method for targeted pharmacogenetic profiling
18.00 - 19.00: PLENARY SESSION DISCUSSION:
Which tests for which drugs should be proposed in routine medical practice and what type of comments should be given (Contra indication? Which molecule to choose in the class? What dose to recommend?)
19.00: Dinner
20.30 - 22.00: POSTER SESSION with Open Bar
| TUESDAY 8 June |
SESSION CHAIR: Ann Daly - Newcastle University Medical School, UK
INTRODUCING LECTURE:
09.00 - 09.30: Pedro Jares - Hospital Clinic, University of Barcelona, ES
Gene expression profiling in cancer
SESSION 3: Personalized cancer treatment: targeting tumour phenotype
09.30 - 10.00: Miguel A. Molina - USP Institut Universitari Dexeus, Barcelona, ES
Pharmacogenetics of EGFR in lung cancer
10.00 - 11.00: Coffee Break and Group Photo
11.00 - 11.30: Simona Soverini - S Orsola-Malpighi Hospital, Bologna, IT
Pharmacogenetics of BCR-ABL in chronic myeloid leukemia
SHORT TALKS:
11.30 - 11.45: Karin Skoglund, Linköping University, SE
Investigation of CYP3A phenotype/genotype correlation and importance for imatinib therapeutic response in chronic myeloid leukemia patients
11.45 - 12.00: Luis Javier Leandro, Spanish National Cancer Research Centre, ES
Identification of genetic markers of sunitinib efficacy and toxicity in first line treatment of renal clear cell carcinoma: A prospective multicenter study
12.00 - 12.15: Ursula Amstutz, University of Bern, CH
Pharmacogenetics of 5-fluorouracil toxicity: influence of polymorphisms in the folate pathway and in pyrimidine metabolism
12.30: Lunch
15.30 - 16.00: Coffee Break
SESSION 4: Personalized cancer treatment: targeting patient genotype
SESSION CHAIR: Céline Verstuyft - Hôpital Bicêtre, Paris, FR
16.00 - 16.30: Hiltrud Brauch - IKP Stuttgart, DE
Pharmacogenomics of tamoxifen
16.30 - 17.00: Mathias Schwab - IKP Stuttgart, DE
Pharmacogenetics of 6 mercaptopurine
17.00 - 17.30: André van Kuilenburg - Academic Medical Center, Amsterdam, NL
Pharmacogenetics of 5-fluorouracil and irinotecan
17.30 - 17.45: Bas Peters, Utrecht University, NL
The PCSK9 E670G polymorphism modifies the effectiveness of statins in reducing the risk of myocardial infarction
17.45 - 18.15: Pierre Laurent-Puig - INSERM, Université Paris V, FR
Pharmacogenomics of EGFR pathways in colon cancer
18.15 - 19.00: PLENARY SESSION DISCUSSION:
Which tests for which drugs should be proposed in routine medical practice and what type of comments should be given (Contra indication? Which molecule to choose in the class? What dose to recommend?)
19.00: Dinner
| WEDNESDAY 9 June |
SESSION CHAIR: Laurent Becquemont - Université Paris-Sud, FR
INTRODUCING LECTURE
09.00 - 09.30: Patrice Jaillon - Hôpital Saint Antoine, Paris, FR
Contribution of pharmacogenetics to clinical pharmacology
SESSION 5: Pharmacogenomics of cardiovascular diseases
09.30 - 10.00: Céline Verstuyft - Hôpital Bicêtre, Paris, FR
Pharmacogenetics of Clopidogrel
10.00 - 10.30: Mia Wadelius - Uppsala Universitet, SE
Pharmacogenetics of oral anticoagulants
10.30 - 11.00: Coffee Break
11.00 - 11.30: Anke-Hilse Maitland-Van der zee - Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), NL
Oral anticoagulant prescribing pharmacogenetic algorythms and point of care genotyping
11.30 - 12.00: Martin Fromm - Erlangen University, DE
Pharmacogenetics of oral hypoglycaemic agents
12.00 - 13.00: PLENARY SESSION DISCUSSION:
Which tests for which drugs should be proposed in routine medical practice and what type of comments should be given (Contra indication? Which molecule to choose in the class? What dose to recommend?)
13.00: Lunch
14.00: Excursion to Girona
18.30 - 19.00: Business Meeting
19.00: Dinner
20.30 - 22.00: POSTER SESSION with Open Bar
| THURSDAY 10 June |
SESSION 6: Pharmacogenomics in drug companies and regulatory agencies
09.30 - 10.00: Felix Frueh - Medco Health Solutions, Bethesda, US
Pharmacogenetics and pharmacogenomics: a health care company perspective
10.00 - 10.15: David Gurwitz - Tel-Aviv University, IL
Growth inhibitory effects of antidepressants in human Lymphoblastoid cell lines: toward depression treatment biomarkers
10.15 - 11.00: Coffee Break
11.00 - 11.30: Marja-Liisa Dahl - Karolinska University Hospital, Clinical Pharmacology, Huddinge, SE
EMEA pharmacogenetics working party: an academic point of view
SHORT TALKS:
11.30 - 11.45: Maria Gabriella Scordo, Uppsala University, SE
CYP2D6, CYP2C19 and CYP2C9 genotyping in a clinical setting in Sweden
11.45 - 12.00: Vita Dolzan, University of Ljubljana, SI
Pharmacogenetics: a step further towards personalized DMARD treatment of rheumatoid arthritis
12.30: Lunch
15.30 - 16.00: Coffee Break
SESSION 7: Pharmacogenomics of organ transplantation
CHAIR: Ingolf Cascorbi, University of Kiel, DE
16.00 - 16.30: Eric Thervet - Hôpital Necker Enfants Malades, Paris, FR
Pharmacogenetics of Calcineurin inhibitors
16.30 - 17.00: Ron van Schaik - Clinical Chemistry (AKC), Rotterdam, NL
Pharmacogenetics of mycophenolic acid
17.00 - 17.30: Evelyne Jacqz-Aigrain - Hôpital Robert Debré, Paris, FR
Pharmacogenetics in pediatric organ transplantation
SHORT TALKS:
17.30 - 17.45: Hansjoerg Rothe, Medical University Innsbruck, AT
Mendelian randomization trials using calcium-sensing receptor gene polymorphism Arg990Gly to mimick calcimimetic therapy
17.45 - 18.00: Janet Coller, University of Adelaide, AU
Impact of donor and recipient ABCB1, CYP3A5 and immune genetics on kidney transplant outcome
CLOSING LECTURE:
18.00 - 18.30: Ingolf Cascorbi, University of Kiel, DE
Consideration of pharmacogenetic information in drug treatment: current recommendations and future
19.30: Drinks Reception
20.00: Conference Dinner
| FRIDAY 11 June |
Departure after breakfast.
